Exelixis, Inc. (NASDAQ:EXEL) said on Tuesday that the FDA approved its CABOMETYX tablets, for the expanded indication of patients with advanced renal cell carcinoma …
Sean Lavin: TRXC investor focus to turn to U.S.
Cowen’s Eric Schmidt sees an extra several hundred million dollars in sales for EXEL in HCC market.
Exelixis, Inc. (NASDAQ:EXEL) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 30% upturn.
